Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 2543026, 6 pages
Research Article

Pain Analysis in Patients with Pancreatic Carcinoma: Irreversible Electroporation versus Cryoablation

1Department of General Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China
2Department of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China

Received 18 August 2016; Revised 31 October 2016; Accepted 29 November 2016

Academic Editor: Helmut Schoellnast

Copyright © 2016 Jiannan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The aim of this article is to evaluate and compare the postprocedure pain in patients with pancreatic carcinoma treated with irreversible electroporation (IRE) and cryoablation (CRYO). We compared 22 patients with 22 lesions in pancreas treated with IRE and 26 patients with 27 lesions treated with cryosurgery. All the patients in the two groups were under celiac plexus block (CPB) treatment to alleviate the postprocedure pain. A numerical rating scale (VAS) consisting of 11-point scales and the 24 h total hydromorphone use were recorded for the analysis of the pain level in the patients who underwent these two technologies separately. Other parameters, such as the complications and the ECOG performance status, were also noted. Statistical analysis was performed by Fisher’s exact test, the Chi-square test, and Student’s -test. All the pancreatic carcinoma patients in our study were reported to have postprocedure pain in the two groups. But there was no significant difference in the mean pain score (4.95 (IRE) versus 4.85 (CRYO); ) and 24 h total hydromorphone use (3.89 mg (IRE) versus 3.97 mg (CRYO); ). IRE is comparable to cryotherapy in the amount of pain that patients with pancreatic carcinoma experience.